571 related articles for article (PubMed ID: 15475948)
41. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21.
Baena E; Ortiz M; Martínez-A C; de Alborán IM
Exp Hematol; 2007 Sep; 35(9):1333-43. PubMed ID: 17637497
[TBL] [Abstract][Full Text] [Related]
42. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.
Takai A; Toyoshima T; Uemura M; Kitawaki Y; Marusawa H; Hiai H; Yamada S; Okazaki IM; Honjo T; Chiba T; Kinoshita K
Oncogene; 2009 Jan; 28(4):469-78. PubMed ID: 18997814
[TBL] [Abstract][Full Text] [Related]
43. Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
Schlott T; Eiffert H; Bohne W; Landgrebe J; Brunner E; Spielbauer B; Knight B
Gynecol Oncol; 2005 Sep; 98(3):409-19. PubMed ID: 16005053
[TBL] [Abstract][Full Text] [Related]
44. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C; Felsher DW
Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
[TBL] [Abstract][Full Text] [Related]
45. Cancer therapy: switching off oncogenes.
Pompetti F; Pilla D; Giancola R
Bioessays; 2003 Feb; 25(2):104-7. PubMed ID: 12539235
[TBL] [Abstract][Full Text] [Related]
46. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
Deutzmann A; Sullivan DK; Dhanasekaran R; Li W; Chen X; Tong L; Mahauad-Fernandez WD; Bell J; Mosley A; Koehler AN; Li Y; Felsher DW
Nat Commun; 2024 Feb; 15(1):963. PubMed ID: 38302473
[TBL] [Abstract][Full Text] [Related]
47. Of mice and men: the nonrandom genomic instability in hepatocarcinogenesis.
Calvisi DF
Hepatology; 2011 Mar; 53(3):723-5. PubMed ID: 21374655
[No Abstract] [Full Text] [Related]
48. [Oncogene c-myc].
Tsujiuchi T; Nakae D; Konishi Y
Nihon Rinsho; 2001 Oct; 59 Suppl 6():116-20. PubMed ID: 11761924
[No Abstract] [Full Text] [Related]
49. Inactivation of MYC reverses tumorigenesis.
Li Y; Casey SC; Felsher DW
J Intern Med; 2014 Jul; 276(1):52-60. PubMed ID: 24645771
[TBL] [Abstract][Full Text] [Related]
50. [File no.47: CMYC].
Soussi T
Bull Cancer; 2001 Nov; 88(11):1053-4. PubMed ID: 11741797
[No Abstract] [Full Text] [Related]
51. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI; Das B; Felsher DW
Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
[TBL] [Abstract][Full Text] [Related]
52. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models.
Felsher DW
Cell Cycle; 2006 Aug; 5(16):1808-11. PubMed ID: 16929172
[TBL] [Abstract][Full Text] [Related]
53. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.
Sullivan DK; Deutzmann A; Yarbrough J; Krishnan MS; Gouw AM; Bellovin DI; Adam SJ; Liefwalker DF; Dhanasekaran R; Felsher DW
Oncogene; 2022 Nov; 41(45):4960-4970. PubMed ID: 36207533
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?
Leon J; Ferrandiz N; Acosta JC; Delgado MD
Cell Cycle; 2009 Apr; 8(8):1148-57. PubMed ID: 19282668
[TBL] [Abstract][Full Text] [Related]
55. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
Wu CH; van Riggelen J; Yetil A; Fan AC; Bachireddy P; Felsher DW
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13028-33. PubMed ID: 17664422
[TBL] [Abstract][Full Text] [Related]
56. c-MYC-induced genomic instability.
Kuzyk A; Mai S
Cold Spring Harb Perspect Med; 2014 Apr; 4(4):a014373. PubMed ID: 24692190
[TBL] [Abstract][Full Text] [Related]
57. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
Beer S; Bellovin DI; Lee JS; Komatsubara K; Wang LS; Koh H; Börner K; Storm TA; Davis CR; Kay MA; Felsher DW; Grimm D
Mol Ther; 2010 Jan; 18(1):161-70. PubMed ID: 19844192
[TBL] [Abstract][Full Text] [Related]
58. Reversible tumorigenesis by MYC in hematopoietic lineages.
Felsher DW; Bishop JM
Mol Cell; 1999 Aug; 4(2):199-207. PubMed ID: 10488335
[TBL] [Abstract][Full Text] [Related]
59. Targeting oncogenes.
Goodman L
J Clin Invest; 2004 Nov; 114(10):1362. PubMed ID: 15545982
[No Abstract] [Full Text] [Related]
60. Addicted to Myc--but why?
von Eyss B; Eilers M
Genes Dev; 2011 May; 25(9):895-7. PubMed ID: 21536730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
